Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.

ABSTRACT: Advances in genomic technologies and the development of targeted therapeutics are making the use of precision medicine increasingly possible. In this study, we explored whether precision medicine can be applied for the management of refractory/relapsed pediatric solid tumors by discovering actionable alterations using targeted panel sequencing. Samples of refractory/relapsed pediatric solid tumors were tested using a targeted sequencing panel covering the exonic DNA sequences of 381 cancer genes and introns across 22 genes to detect clinically significant genomic aberrations in tumors. The molecular targets were tiered from 1 to 5 based on the presence of actionable genetic alterations, strength of supporting evidence, and drug availability in the Republic of Korea. From January 2016 to Oc

SUBMITTER: Lee JW 

PROVIDER: S-EPMC6867621 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature